TABLE 1.
Patient Demographic and Clinical Characteristics
| LBN → Timolol (Tx Sequence 1), n = 24 | Timolol → LBN (Tx Sequence 2), n = 26 | Overall, N = 50 | P Valuea | |
|---|---|---|---|---|
|
| ||||
| Patient characteristics | ||||
| Age (y) (95% CI) | 66.7 (63.4–70.1) | 68.4 (64.8–72.1) | 676 (65.2–70.1) | .48 |
| Gender, n (%) | ||||
| Female | 14 (60.9) | 19 (70.4) | 33 (66.0) | .56 |
| Male | 9 (39.1) | 8 (29.6) | 17 (34.0) | |
| Ethnicity, n (%) | ||||
| African American | 1 (4.3) | 1 (3.7) | 2 (4.0) | .30 |
| Asian | 0 (0.0) | 2 (7.4) | 2 (4.0) | |
| White | 17 (73.9) | 22 (81.5) | 39 (78.0) | |
| Other | 5 (21.7) | 2 (7.4) | 7 (14.0) | |
| Hypertension, n (%) | ||||
| No | 16 (69.6) | 18 (66.7) | 34 (68.0) | 1.00 |
| Yes | 7 (30.4) | 9 (33.3) | 16 (32.0) | |
| Diabetes, n (%) | ||||
| No | 22 (95.7) | 27 (100.0) | 49 (98.0) | .46 |
| Yes | 1 (4.3) | 0 (0.0) | 1 (2.0) | |
| Eye Characteristics (95% CI) | ||||
| 24-2 MD | −1.04 (−2.35 to 0.27) | −1.22 (−2.02 to −0.41) | −1.14 (−1.85 to −0.42) | .81 |
| 24-2 PSD | 2.59 (1.61–3.58) | 1.91 (1.74–2.08) | 2.22 (1.77–2.67) | .17 |
| 10-2 MD | −0.67 (−1.68 to 0.33) | −0.75 (−1.51 to 0.02) | −0.71 (−1.31 to −0.12) | .90 |
| 10-2 PSD | 2.08 (0.86–3.30) | 1.36 (1.23–1.48) | 1.67 (1.15–2.19) | .23 |
| Baseline IOP (mm Hg) | 22.3 (19.9–24.8) | 25.2 (21.3–29.1) | 23.9 (21.5–26.2) | .21 |
| Baseline CCT (μm) | 564.4 (552.2–576.6) | 548.5 (537.6–559.4) | 555.8 (5476–564.0) | .05 |
| Eye classification, n (%) | ||||
| Glaucoma | 6 (26.1) | 8 (29.6) | 14 (28.0) | .94 |
| Healthy | 5 (21.7) | 5 (18.5) | 10 (20.0) | |
| Ocular hypertension | 12 (52.2) | 14 (51.9) | 26 (52.0) | |
CCT = central corneal thickness; CI = confidence interval; IOP = intraocular pressure; LBN = latanoprostene bunod; MD = mean deviation; PSD = pattern standard deviation; Tx = treatment.
a
P < .05 is considered statistically significant